Loading...
Loading...
The 'Triple G' Agonist. The evolution of weight loss: GLP-1 + GIP + Glucagon.
The "Triple G" Agonist. While Ozempic stops hunger and Mounjaro improves insulin, Retatrutide actively increases Resting Metabolic Rate via Glucagon.
Stops Hunger.
Stops Hunger + Fixes Insulin.
Stops Hunger + Fixes Insulin + Burns Energy.
Most people think Glucagon is "bad" because it raises blood sugar. But in the liver, Glucagon signalling increases autophagy and lipid oxidation (burning fat for heat).
| Week | Dose |
|---|---|
| 1-4 | 2mg Weekly |
| 5-8 | 4mg Weekly |
| 9-12 | 6mg Weekly |
| Max | 12mg Weekly |
Problem: Retatrutide raises RHR more than any other GLP-1.
Solution: Must monitor with Oura/Apple Watch. If RHR increases >15bpm from baseline, DO NOT increase dose. Ensure hydration is doubled.
"The glucagon component is the game changer. We aren't just suppressing appetite; we are turning the liver into a fat-burning furnace."— Dr. Tyna Moore
~30-40% more potent. Preserves more lean muscle due to Glucagon mechanism.
Remarkably, yes. cleared Fatty Liver Disease (NAFLD) in >85% of patients.
"GLP-1 agonists are arguably the most impactful drugs of the century, but if you lose muscle while on them, you are trading diabetes for frailty. Resistance training is not optional."
Metabolic health and muscle preservation
— Outlive (2023)"If you're on a GLP-1 agonist and not doing resistance training, you're trading metabolic health for frailty. Muscle loss on these drugs is real and preventable with proper training."
GLP-1 agonists and muscle preservation
— The Drive Podcast"The next generation of metabolic therapeutics will be triple agonists like Retatrutide. Combining GLP-1, GIP, and Glucagon activation addresses multiple pathways simultaneously—not just appetite suppression, but actual metabolic rate enhancement."
Future of metabolic therapeutics
— The Drive Podcast